Lobe Sciences Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LOBEF research report →
About the company
Lobe Sciences Ltd. is a life sciences company focused on researching and advancing psychedelic-based medicines. Their primary therapeutic development involves psilocybin-derived treatments combined with N-acetylcysteine, specifically for addressing mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD).
- CEO
- Frederick Dominick Sancilio
- IPO
- 2023
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $1.41M
- P/E
- -4.20
- P/S
- 0.00
- P/B
- 88.52
- EV/EBITDA
- -2.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 4099.95%
- ROIC
- -311.75%
- Revenue
- $0 · -100.00%
- Net Income
- $-4,424,660 · -0.08%
- EPS
- $-0.03 · 11.88%
- Op Income
- $-4,176,322
- FCF YoY
- -116.31%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.07
- Avg Volume
- 74.43K
Get TickerSpark's AI analysis on LOBEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LOBEF coverage
Recent articles, reports, and earnings notes.
No research on LOBEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LOBEF report →Similar companies
Peers in the same neighborhood.